1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Jasper’s Briquilimab Stands Up To Competition, But Investors Bail

 
• By Jessica Merrill

The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.

(Shutterstock)

Jasper Therapeutics’ c-Kit inhibitor, briquilimab, demonstrated efficacy in a Phase II trial in patients with chronic spontaneous urticaria (CSU) that appears on par with rival Celldex’s barzolvolimab. However, the small data set and some questions about dosing may have spooked investors, with the company’s stock opening down 50% at $8.74 on 8 January then dropping further to close the day at $6.99, despite the generally positive results.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

More from Immunological

Crunch Time Close For Abivax’s IBD Ambitions

 
• By Kevin Grogan

Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.

Stelara Biosimilars Storm US Market With 85% Discounts Ahead Of Price Drop In Medicare

 
• By Cathy Kelly

The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.

Sanofi Advances Immunology Ambitions With Dren Deal

 
• By Kevin Grogan

The France-based giant inks a transaction potentially worth around $1.9bn to get hold of Dren Bio’s autoimmune disease treatment DR-0201.